Scientific Article
Evaluation Of Research On WHO ‘Best Buys’ NCDs Interventions

Author
Luke N Allen, Jessica Pullar, Kremlin Khamarj Wickramasinghe (E-mail: kremlinkw@gmail.com), Julianne Williams, Nia Roberts, Bente Mikkelsen, Cherian Varghese, Nick Townsend
Citation
Evaluation of research on interventions aligned to WHO ‘Best Buys’ for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015 Luke N Allen, Jessica Pullar, Kremlin Khamarj Wickramasinghe, Julianne Williams, Nia Roberts, Bente Mikkelsen, Cherian Varghese, Nick Townsend BMJ Global Health Feb 2018, 3 (1) e000535; DOI: 10.1136/bmjgh-2017-000535
  • Source
    BMJ Global Health
  • Release date
    19/02/2018

Evaluation of research on interventions aligned to WHO ‘Best Buys’ for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015

Key questions

What is already known about this topic?

  1. The WHO published a number of highly cost-effective non-communicable disease (NCD) policy options—dubbed ‘best buys’—that are included in the Global Action Plan for the prevention and control of NCDs.
  2. Low-income and middle-income countries face the greatest burden of NCDs and have been encouraged to implement these polices as a priority.
  3. The ‘best buys’ are identified from the global evidence base, but it is unclear how many research activities are carried out in low-income and lower-middle-income countries (LLMICs) related to these priority NCD actions.

What are the new findings?

  1. There is a general lack of published evidence for the ‘best buy’ interventions in LLMICs, and a number of the interventions have not been evaluated at all in these settings.
  2. Most of the existing research is concentrated in South-East Asia. The researchers’ search only returned five studies from the African region, two from the Eastern Mediterranean, two from South-East Asia, one from the Americas, and none from the European or Western Pacific regions.
  3. More than half of the identified studies evaluated tobacco-related interventions.

Recommendations for policy

  1. This study highlights the need for prioritising NCD ’best buys’ in national research agendas in LLMICs. This would contribute to the generation of more ‘context specific’ evidence for NCD prevention and control, and improve the implementation of those policies.
  2. Countries that introduce ’best buys’ should try to evaluate these interventions and publish findings in the public domain.

Abstract

Background

Non-communicable diseases (NCDs) are the leading cause of death and disability worldwide, with low-income and middle-income countries experiencing a disproportionately high burden. Since 2010 WHO has promoted 24 highly cost-effective interventions for NCDs, dubbed ‘best buys’. It is unclear whether these interventions have been evaluated in low-income and lower-middle-income countries (LLMICs).

Aim

To systematically review research on interventions aligned to WHO ‘best buys’ for NCDs in LLMICs.

Methods

The researchers searched 13 major databases and included papers conducted in the 83 World Bank-defined LLMICs, published between 1 January 1990 and 5 February 2015. Two reviewers independently screened papers and assessed risk of bias. We adopted a narrative approach to data synthesis. The primary outcomes were NCD-related mortality and morbidity, and risk factor prevalence.

Results

The researchers identified 2672 records, of which 36 were included (608 940 participants). No studies on ‘best buys’ were found in 89% of LLMICs. Nineteen of the 36 studies reported on the effectiveness of tobacco-related ‘best buys’, presenting good evidence for group interventions in reducing tobacco use but weaker evidence for interventions targeting individuals. There were fewer studies on smoking bans, warning labels and mass media campaigns, and no studies on taxes or marketing restrictions. There was supportive evidence that cervical screening and hepatitis B immunisation prevent cancer in LLMICs. A single randomised controlled trial supported polypharmacy for cardiovascular disease. Fourteen of the ‘best buy’ interventions did not have any good evidence for effectiveness in LLMICs.

Conclusions

The researchers found studies on only 11 of the 24 interventions aligned with the WHO ‘best buys’ from LLMIC settings. Most LLMICs have not conducted research on these interventions in their populations. LLMICs should take action to implement and evaluate ‘best buys’ in their national context, based on national priorities, and starting with interventions with the strongest evidence base.

Source Website: BMJ Global Health